Tallac Therapeutics

Tallac Therapeutics, Inc – Landing page

Burlingame, United States · Founded 2018 · $182.0M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$182.0M
Last Round
$120.0M Series BMay 2024
Rounds
2

About

Tallac Therapeutics is a privately held clinical-stage biopharmaceutical company based in Burlingame, California, focused on harnessing innate and adaptive immunity to fight cancer. The company's proprietary Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform delivers a potent TLR9 agonist for targeted immune activation via systemic administration, enabling a new class of immunotherapy candidates for solid tumor malignancies. Founded in 2018 by Drs. Corey Goodman and Hong I. Wan along with two co-founders, Tallac raised $62 million in Series A financing in 2020 and subsequently closed additional rounds to fund its clinical pipeline.

Summary

Tallac Therapeutics is a Biotech company based in Burlingame, United States, founded in 2018. It has raised $182.0M in total across 2 rounds, most recently a $120.0M Series B round in May 2024. Investors include TCGX, Horizon Technology Finance and venBIO Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMay 2024
$120.0M

Sign up to see all 3 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tallac Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/tallac-therapeutics"><img src="https://indexed.vc/api/badge/company/tallac-therapeutics" alt="Tallac Therapeutics on Indexed.vc" width="260" height="76" /></a>